• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sunshine Biopharma Inc. - Common stock (NQ:SBFM)

0.5164 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sunshine Biopharma Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’ ↗
June 11, 2025
CEO Steve Slilaty stated that the company is aiming to strengthen its presence in Canada’s generic drugs market, valued at $9.4 billion. 
Via Stocktwits
News headline image
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market
June 11, 2025
Via ACCESS Newswire
News headline image
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year
May 15, 2025
Via ACCESS Newswire
News headline image
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market
May 06, 2025
Via ACCESS Newswire
News headline image
Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug ↗
April 21, 2025
Its subsidiary launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market. 
Via Stocktwits
News headline image
The market is filled with gapping stocks in Monday's session. ↗
April 21, 2025
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
What's going on in today's pre-market session ↗
April 21, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion
April 21, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
April 21, 2025
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
April 17, 2025
 
Via Benzinga
News headline image
BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Secures $2.46M in Registered Direct
April 03, 2025
Via Investor Brand Network
News headline image
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering
April 03, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
April 03, 2025
 
Via Benzinga
News headline image
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
April 02, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
April 02, 2025
 
Via Benzinga
News headline image
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug ↗
April 02, 2025
Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 million. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
April 02, 2025
 
Via Benzinga
News headline image
Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer
April 02, 2025
Via ACCESS Newswire
News headline image
US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia ↗
April 02, 2025
U.S. stock futures slipped on Wednesday after a mixed session on Tuesday. Futures of major benchmark indices were lower in premarket trading. 
Via Benzinga
News headline image
Why Sportsman's Warehouse Shares Are Trading Higher By Around 39%; Here Are 20 Stocks Moving Premarket ↗
April 02, 2025
 
Via Benzinga
News headline image
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
April 01, 2025
Via ACCESS Newswire
News headline image
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada
March 24, 2025
Via ACCESS Newswire
News headline image
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
March 10, 2025
Via ACCESS Newswire
News headline image
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
January 21, 2025
Via ACCESS Newswire
News headline image
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
January 15, 2025
Via ACCESSWIRE
News headline image
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
December 09, 2024
Via ACCESSWIRE
News headline image
Sunshine Biopharma Launches a New Generic Prescription Drug
December 04, 2024
Via ACCESSWIRE
News headline image
Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma
December 02, 2024
Via ACCESSWIRE
News headline image
Sunshine Biopharma Launches a New Generic Prescription Drug
November 22, 2024
Via ACCESSWIRE
News headline image
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%
November 06, 2024
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap